NEJM Medical Study: CBD has been found effective in reducing seizures in young children with severe, drug-resistant forms of epilepsy. Over a 14 week trial, 120 patients where given either a placebo or a 20 mg does of cannabidiol (CBD). Those that received CBD during the trial, reported a 50% drop in the number of weekly seizures. The median average number of seizures dropped from 12.4 to 5.9 per week.
Moreover, 5% of patients saw total remission – 0 seizures!
Among those that received CBD, 5% stopped having seizures altogether. Consider this: there is currently no FDA-approved treatment for Dravet syndrome. None. And now CBD has the potential to become the first and only medicine found effective to treat a form of epilepsy so severe that it kills 1 in 5 by age 20.
The findings of this double-blind study were published this week in the New England Journal of Medicine (NEJM), and demonstrate the effectiveness of cannabidiol (CBD) | Epidiolex in treating severe drug-resistant forms of epilepsy such as Dravet syndrome. CBD is the principle non-psychoactive compound found in marijuana and hemp. For this study, CBD was provided in the form of Epidiolex – a marijuana based formulation of CBD manufactured by GW Pharmaceuticals. More on GW Pharma in a bit.
And yet just this week, ‘acting’ DEA Chief Chuck Rosenberg reiterated that in his view – ‘marijuana is not medicine.’ It would seem Chuck, that the New England Journal of Medicine may just disagree with you on that point. Maybe it’s a good thing your just ‘acting’ DEA Chief.
The fact that this trial’s findings were published in the NEJM – one of the most respected peer-reviewed medical journals published, is a very big deal and a huge endorsement as to the study’s authenticity, veracity and medical significance. It’s also a big thumbs up for Epidiolex, the CBD formulation used in the study.
There were some drawbacks found during the study. Of the 120 patients in the trial, 8 withdrew due to perceived side-effects which included fatigue, fever and severe diarrhea.
The study was funded by GW Pharmaceuticals, a UK based pharmaceutical company that specializes in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals manufactures Epidiolex, the marijuana based CBD medicine that was used in this study. Epidiolex is currently finishing Phase 3 clinical trials as a treatment for two severe forms of epilepsy: Dravet syndrome, and Lennox-Gastaut syndrome. Epidiolex is also being studied as a possible treatment for Tuberous Sclerosis and Infantile Spasms.
If you, or someone you know, is suffering from these severe forms of epilepsy – let them know that there may be help on the horizon. In addition, the patient’s physician can contact GW Pharma for more information on GW-sponsored clinical trails by emailing here: email@example.com.
On NASDAQ: GWPH | For investor relations click here